Boston Scientific's Watchman FLX gains traction despite stock slump and slower growth forecasts

Boston Scientific (BSX) has faced a challenging year, with its stock dropping sharply since January. The company's Watchman FLX device, designed to reduce stroke risk in atrial fibrillation patients, has shown strong clinical results but has not shielded the firm from broader market pressures. Recent adjustments by analysts now reflect slower growth expectations in key segments.

In March 2024, the CHAMPION-AF trial results were published, comparing the Watchman FLX device to traditional anticoagulants. The study confirmed the device's non-inferiority in preventing strokes, though ischemic stroke rates were slightly higher at 3.2% compared to 2% for medications. Despite this, users experienced fewer non-procedural bleeding complications, meeting the trial's primary safety goal.

The findings led to a surge in global adoption. By early 2026, key medical centres—including the Cleveland Clinic, Charité Berlin, and Mount Sinai Hospital—reported a 40% increase in Watchman FLX procedures. Improved safety data and expanded FDA approvals drove this growth. Yet, financial analysts have adjusted their outlook. Raymond James lowered its 2026 and 2027 revenue projections for BSX by 0.5% and 1.5%, respectively, citing slower growth in U.S. electrophysiology and Watchman segments. These areas had previously contributed over half of the company's year-to-year revenue gains. The firm also downgraded BSX from *Strong Buy* to *Outperform* and reduced its price target from $97 to $88. Despite the downgrade, multiple research firms still recommend BSX as a *Buy* or *Outperform*, with targets ranging from $88 to $120. Marty Leon, the trial's co-principal investigator, called the results a strong endorsement for wider clinical use. Ken Stein, Boston Scientific's chief medical officer, highlighted that stroke rates in both study groups remained *incredibly low*. On the trading floor, BSX shares closed at $62.93, a 9% drop and the lowest point since January 2024. Year-to-date, the stock has fallen 34%, underperforming the S&P 500's 7.1% decline.

Boston Scientific's Watchman FLX continues to gain traction in hospitals worldwide, supported by positive trial outcomes and regulatory approvals. However, the company's stock performance remains under pressure, with shares near their lowest in over a year. Analysts have tempered revenue expectations, though many still see long-term potential in the device's market expansion.